PNPLA3 gene variants in people with fatty liver disease in overseas territories
Looks at PNPLA3 gene variants in adults with metabolic fatty liver disease.
Plain-language title generated from the registry record
Registry title: Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Key facts
- Where
- Saint-Denis, RéunionSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with fatty liver disease linked to weight or metabolic problems, seen at hospitals in Guadeloupe, French Guiana or Réunion Island.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Fatty liver disease (MASLD): fat in the liver together with overweight or obesity, type 2 diabetes, or metabolic syndrome.
- Biomarker or test result
- The study looks at PNPLA3 gene variants. The record does not ask for a specific result to join.
Main reasons for not taking part
- Under 18 years old
- Cannot give informed consent, or in a vulnerable situation such as guardianship or judicial protection
- Another cause of chronic liver disease, such as hepatitis B, C or E, autoimmune hepatitis, Wilson's disease or hemochromatosis
- Alcohol use above 30 g/day for men or 20 g/day for women
- Pregnant women
Read by machine on 12 November 2026.
Where in Réunion
- Centre Hospitalier Universitaire de la RéunionSaint-Denis, RéunionContact: Sandy Kwiatek, MDNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Hospitalier Universitaire de la Guadeloupe
- Trial code
- NCT07330830
- Record updated
- 9 January 2026
- Original description
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity. Analysis of PNPLA3 polymorphisms in an overseas territories population of MASLD would be interesting to describe their profile susceptibility to develop Metabolic dysfunction associated steatohepatitis (MASH).Read full original descriptionShow less
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity. Analysis of PNPLA3 polymorphisms in an overseas territories population of MASLD would be interesting to describe their profile susceptibility to develop Metabolic dysfunction associated steatohepatitis (MASH).
Exclusion: Presence of another cause of chronic liver disease, including:; Viral hepatitis (B, C, or E); Primary biliary cholangitis or primary sclerosing cholangitis; Autoimmune hepatitis; Wilson's disease; Hemochromatosis; Alpha-1 antitrypsin deficiency; Alcoholic liver disease, or daily alcohol consumption >30 g/day for men or >20 g/day for women; -Pregnant women; Patients under 18 years of age; Patients unable to provide informed consent; so-called vulnerable populations (individuals under guardianship, judicial protection, etc.).
IInclusion Criteria; -Adult patients (≥18 years old) seen in consultation or hospitalized in the Hepato-Gastroenterology Departments of the University Hospitals of Guadeloupe, French Guiana, and Réunion Island, with a diagnosis of MASLD; MASLD is defined as evidence of hepatic steatosis associated with overweight/obesity, type 2 diabetes, or metabolic syndrome according to ATP III (2005) criteria; Patients affiliated with, or beneficiaries of, a social security scheme; Free, informed, and written consent obtained from the participant and signed by both the participant and the investigator (no later than the day of inclusion and prior to any procedure required by the study).